13 January 2020 - Registration enabling study expected to begin dosing in the second or third quarter of this year.
Inhibrx announced today the U.S. FDA granted fast track designation to INBRX-109 for the treatment of patients with unresectable or metastatic conventional chondrosarcoma.
INBRX-109 is a precisely engineered tetravalent single domain antibody based therapeutic candidate that agonises death receptor 5 to induce tumour selective programmed cell death.